1. Overcome barriers to entry: embrace
an access-based marketing strategy
Sandton, Johannesburg | March 8–9 | The only forum connecting pharma, government and payers
COMMERCIAL EXCELLENCE AND MARKET ACCESS
SOUTH AFRICA 2016
www.eyeforpharma.com/southafrica
Collaborate
Establish relationships with all
your key stakeholders, industry
leaders and innovators
Network
Spend over 6 hours networking
with 100+ pharma, experts, payers
and key decision makers
Learn
25+ thought leaders help you maximize
your learning in just 2 days with industry-led
agenda case studies and panel discussions
#efpCEMA
Dr Konji Sebati
CEO
IPASA
Jaime César de Moura
Oliveira
Immediate Past Director
ANVISA (Brazilian FDA)
Inez Naidu
Head of Medicines
Unit
Discovery Health
Gerrit Doevendans
Head of Market
Access South Africa
Boehringer
Ingelheim
Gerdi Strydom
Head of Health & Value,
Southern Africa
Pfizer
Belinda Bhoodoo
Director, Corporate
Affairs & Market
Access
Eli Lilly & Co
FOSTER COLLABORATIVE THINKING
and consensus amongst various stakeholders
REMOVE BARRIERS TO PRESCRIBING
Encourage cross-functional working across your 3Ms:
• Marketing • Market Access • Medical teams
DESIGN WITH YOUR PAYERS
Don’t just design your strategy for payers, design it with them –
and build long-term partnerships
MAP YOUR MARKET WITH INTELLIGENCE
AND PRECISION
And better prepare for future submissions
Gold Sponsor Strategic Partners Media Partners
Limited
Passes
Available

2. CEMA South Africa 2016 is the arena for senior level pharma executives
across the 3Ms (Market Access, Marketing and Medical). They’ll be joining
government, private medical aids, payers and key decision makers who are
keen to escape silos and learn how to best work together to build a more
robust and widely accessible healthcare system for South Africa.
The summit will help the commercial, marketing and medical teams to work
together to ensure the message shared to all stakeholders is consistent.
Furthermore, you’ll have the opportunity to get clear guidelines from
government and payers in terms of what they need from you in order
to guarantee market entry and patient access to essential medicines.
Over 2 days this event will inspire constructive debate and foster
collaboration; it has been specially designed for South African pharma and
is the only one to finally give pharma a voice. Not only will you learn from
keynote panels, exclusive case studies and real life business models from
25+ expert speakers, you’ll also have the opportunity to speak directly
with the key decision makers. This is an event only for those who are serious
about tackling the obstacles preventing South African health development.
With all of this at your fingertips, you’ll leave with genuine insights on how
to achieve true commercial success and remove barriers to prescribing.
Reserve your place amongst the most innovative minds in commercial,
marketing and market access – visit our website to register;
www.eyeforpharma.com/southafrica or use the registration form enclosed.
See you in Johannesburg!
Welcome to the eyeforpharma
Commercial Excellence and Market
Access (CEMA) 2016 Summit! Here’s what attendees have
said about our previous
commercial and market
access events...
Don’t just take
our word for it
“I found the congress exceptionally
informative especially at this
time when the pharma industry is
going through a major change in
defining new commercial model”
Quentin van der Merwe
Sales Excellence, Director
GlaxoSmithKline
“I came away from the conference
feeling like I had some useful
insights to share with my
colleagues and ideas that could
be implemented easily to further
enhance our strategy”
Carlyn Villani
Brand Manager
Roche
“A fascinating meeting of diverse
speakers who outlined numerous
themes around the need to prove
the validity and trustworthiness
of RWE, versus RCTs, with
an emphasis on “real time”
versus “real world”. Thank you
eyeforpharma!”
Karel Mechelse
Market Access Strategy Leader
Bayer
“Marketing with a purpose is
all about creating unique and
sustained value for patients and
families...enabling them with
differentiated solutions to live
the life they choose rather than
one dictated by the disease”
Bharat Tewarie
EVP Chief Marketing Officer
UCB
Achieve real pharma-
payer collaboration to
streamline market access
• Speak directly with
Discovery Health and
Metropolitan to better
understand the decision
making process and develop
a better strategy for your
future submissions
• Learn what physicians
find valuable and start
supporting them to build
long-term relationships
and secure optimal
market share
Optimize pricing and
provision to guarantee
entry to market
• Make the shift from
maximum to optimum
pricing to create a
sustainable business model
• Evaluate strategies to address
supply security and discuss
how pharma can collaborate
with government to ensure
access to essential medicines
• Work with the Pricing
Committee to develop a
winning methodology in
preparing HTA dossiers
Master cross-functional
collaboration to increase
patient access to essential
drugs and boost returns
• Integrate a market access
approach into your
marketing strategy to
ensure a consistent message
with all customers and
stakeholders
• Improve the reputation
of sales teams despite
reduced resources
Agenda at a glance
www.eyeforpharma.com/southafrica
Shakira Browne
Head of Commercial Excellence
South Africa
Giselle Quartin
Head of Marketing
South Africa
Blair Gottscho
Head of Operations

3. Speaker faculty includes:
Inez Naidu
Head of Medicines Unit
Discovery Health
Belinda Bhoodoo
Director, Corporate
Affairs Market Access
Eli Lilly Co
Martin van den Berg
Head of Marketing
Boehringer Ingelheim
Avinash Dhaniraj
Head of Commercial
Mylan
Gerdi Strydom
Head of Health Value,
Southern Africa
Pfizer
Jacques Snyman
Head of South Africa
ISPOR
Gerrit Doevendans
Head of Market Access
South Africa
Boehringer Ingelheim
Ali Hamdulay
General Manager,
Provider Networks
Metropolitan
Tania Lennon
Head Of Executive Leadership,
Talent Teams Practice
Korn Ferry Hay Group
Tom Molokoane
Head of Market Access
Novo Nordisk
Dr Konji Sebati
CEO
IPASA
Jaime César de Moura
Oliveira
Immediate Past Director
ANVISA (Brazilian FDA)
Dr. Jacqui Miot
Health Economist, Researcher
and Senior Lecturer
University of Witwatersrand
Prof Morgan Chetty
Medical Doctor, Deputy Chairman
SAMCC
CEO, KwaZulu Natal Managed
Care Coalition
Lauren Pretorius
CEO
Campaigning for Cancer
Jessica Kolberg
Business Unit Manager,
Speciality Care Division
Neonatology Oncology
Abbvie
Dr. João Carapinha
Senior Market Access
Analyst
Carapinha Company
Karina Rogers
Marketing Manager
Aurobindo Pharma
Vaychel Raman
Head of Market Access
Novartis
Shelley McGee
Healthcare Policy
Patient Access Manager
Sanofi
Niel Dass
General Manager
Kenza Health
Marc Blockman
Associate Professor, Division
of Clinical Pharmacology
University of Cape Town
Committee Member
Medicines Control Council
Committee Member
Essential Drugs List
www.eyeforpharma.com/southafrica
Wesley Hughes
Customer Excellence
Manager
Abbvie

4. SECTION 1
‘South Africa needs us’
KEYNOTE MARKET ACCESS DEBATES
This series of three expertly moderated panels examines some
of the most contentious issues from all sides in order to encourage
co-operation and understanding between different counterparties
Risk sharing in South African healthcare
• The case for and against risk sharing and appraisal of motives
• Examples where risk sharing has and hasn’t worked
• The suitability of international models for the South African market
• What forms of risk sharing could be considered?
• How could these be implemented in a South African context?
What governance and frameworks are required?
Standardize pharmacoeconomic analysis to
drive towards a unified HTA
• What is the requirement for guidelines or a unified HTA process?
How big an impact will guidelines around cost effectiveness models
have on both the pharmaceutical industry and payer?
• Breaking the deadlock on voluntary submissions: how can pharma
be motivated to partake and how important is it?
• How can a standardized submission process best be introduced
to enable optimum productivity?
• How could the roll-out of the standardized HTA work and in what
time frame could this happen?
How to avoid stock-outs and get drugs
to your patients quicker
• How big an impact have stock-outs had on the South African
healthcare system?
• What have been the driving forces behind them?
• What solutions are there on both the industry and government
side to address this?
• When will budget from the Ministry of Finance enable the
implementation of new electronic systems?
• What experiences have there been in other countries?
• How can we best collaborate to ensure access to essential medicines?
EXECUTIVE PANELISTS
Dr Konji Sebati
CEO
IPASA
Inez Naidu
Head of Medicines Unit
Discovery Health
Marc Blockman
Associate Professor, Division
of Clinical Pharmacology
University of Cape Town
Committee Member Medicines Control Council
Committee Member Essential Drugs List
Jacques Snyman
Head of South Africa
ISPOR
SECTION 2
Achieve real pharma-payer
collaboration to optimize access
for all parties
High Cost Specialty Medicines in SA –
Industry Challenges and Opportunities
• The medicine cost experience and utilisation : Discovery Health
Medical Scheme perspective
• Find out how the Medicine Pricing Framework in South Africa
impacts successful collaboration with all the stakeholders
• What are the Risk Sharing Access Opportunities in South Africa and
how you can take advantage of upcoming opportunities
Inez Naidu
Head of Medicines Unit
Discovery Health
Standardization of requirements and processes:
what the challenges are, what can be done in
the current atmosphere, and beyond?
• Comprehend the current managed care market landscape and the
differences in processes that leads to difficulties in standardizing
requirements
• Learn the scope of what can be standardized in the current scenario
and how different service providers can join forces to achieve it
• Recognize what steps need to be put in place in order to achieve a
greater degree of harmonization amongst competing players in the
space, for the betterment of the South African patient
Ali Hamdulay
General Manager,
Provider Networks
Metropolitan
Develop long-term partnerships between
Pharma and medical practitioners
• What do Medical Practitioners need to know about Pharmaceutical
products
• 2Health Care Reform- The impact on Health Care systems and Pharma
• Patient access to medicines and the challenges involved
Prof Morgan Chetty
Medical Doctor, Deputy
Chairman, SAMCC
CEO, KwaZulu Natal Managed
Care Coalition
Achieve long term engagement with patients
for holistic healthcare and optimal follow up
• Learn which initiatives involving long-term patient engagement
have worked well in both the public and private sector
• Examine case studies of badly managed engagement, for example TB
• Identify which available tools we are underutilizing in order
to improve patient engagement
• Witness innovative frameworks and how to implement them
to engage and include medical staff
Jessica Kolberg
Business Unit Manager,
Speciality Care Division
Neonatology Oncology
Abbvie
Conference Agenda
www.eyeforpharma.com/southafrica

5. INTERNATIONAL SPOTLIGHT:
Lessons from beyond Africa
Establish public-private partnerships in a
developing and economically diverse market:
A case study on Brazil
This session will examine experiences from Brazilian markets on how
they have addressed some of the challenges that the South African
healthcare system is facing.
• Hear directly from ANVISA how they made key changes for a public-
private partnership and how they decided timelines for roll-out
• Understand the reactions of the government and private sector along
the way to best anticipate potential challenges
• Witness how the Brazilian frameworks for public-private partnerships
could be transferred to the South African market and identify the
differences that could prove stumbling blocks
• Learn how the government and the private sector can support each
other through the process
Jaime César de Moura
Oliveira
Immediate Past Director
ANVISA (Brazilian FDA)
Apply international insights and gap analysis
to South Africa to strengthen market access
• Identify quality gaps in pharmacoeconomic research in South Africa
to improve patient access.
• Highlight policy gaps in South Africa to strengthen market access policy.
• Explore pricing gaps in South Africa to boost patient access through
floors, ceilings and corridors on pharmaceutical prices.
• Apply international research in South Africa to fill the gaps and drive
innovation
Dr. João Carapinha
Senior Market Access
Analyst
Carapinha Company
SECTION 3
Optimize pricing and business
strategy to best supply medicines
to the market
PANEL: Make the shift from maximum to
optimum pricing to create a sustainable
business model
• Debate how to balance short-term targets with a long-term vision
on healthcare and sales to ensure future profitability
• Examine the way South Africa is approached by headquarters in relation
to other BRIC nations and whether this impacts on pricing options
• Understand to what extent European market dynamics relate
to South Africa and what aspects can be applied
• Discuss the viability of a dual strategy for both the public and private
sector and how it can be effectively implemented
• Pinpoint what is needed from government and payers to support this
Gerrit Doevendans
Head of Market Access
South Africa
Boehringer Ingelheim
Belinda Bhoodoo
Director, Corporate
Affairs Market Access
Eli Lilly Co
Shelley McGee
Healthcare Policy Patient
Access Manager
Sanofi
Navigate through current CAMS legislation
to establish and maintain a sustainable brand
• Steer your business in alignment with CAMS to overcome existing
uncertainty and strategize your business going forward
• Optimize consumer, brand and market insights to design an effective
and actionable plan for your business
Niel Dass
General Manager
Kenza Health
Develop a winning methodology in preparing
and submitting dossiers for HTAs
• Learn what costs you should and shouldn’t be including in your
pharmacoeconomic assessments
• Overcome the challenge of a lack of local data and effectively
model disease burden on society
• Ensure you develop a clear message and value proposition by
recognizing the common mistakes and avoiding them
• Understand how to engage effectively with your payers
Shelley McGee
Healthcare Policy Patient
Access Manager
Sanofi
Dr. Jacqui Miot
Health Economist, Researcher
and Senior Lecturer
University of Witwatersrand
www.eyeforpharma.com/southafrica
Conference Agenda
Foster collaboration to deliver value
throughout your organisation to patients
• Understand how different parts of the organisation need to work
together to deliver value for patients, payers, and physicians
• Learn how to break down silos to reduce the barriers to necessary
collaborations
• Hear how the challenges encountered by organisations as they work
to succeed in today’s collaborative pharma environment are uncovered
• Drawing on research from the sector, look at how organisations can
create the individual, team and organizational capability to support
real collaboration in increasingly complex healthcare systems
Tania Lennon
Head Of Executive Leadership,
Talent Teams Practice
Korn Ferry Hay Group

6. SECTION 4
Master cross-functional
collaboration to ensure
commercial excellence in
a modern healthcare system
Integrate market access into your marketing
strategy in order to maximize commercial
returns
• Attitude based change – learn how to help marketing teams
understand the role of market access to encourage collaboration
from the ground up
• Hear key strategies to avoid information being lost and
miscommunicated between teams internally
• Ensure a consistent message with your customers and key
stakeholders by understanding how to integrate a market access
approach into your marketing strategy
• Understand how to integrate market access into your key account
strategy into marketing strategy to improve brand value
Gerdi Strydom
Head of Health Value,
Southern Africa
Pfizer
Achieve sales force effectiveness in an
increasingly saturated market place
• The decline of the traditional sales rep model - Learn how
to effectively work with reduced resources
• Discuss strategies to improve the reputation of the sales rep
to gain more open communication with clients
• Learn from best practices on how to manage key accounts and
optimize CRM systems to better work with clients
• Out of industry: Lessons learnt from other sectors on how they
continue to increase commercial returns in the South African market
Avinash Dhaniraj
Head of Commercial
Mylan
Incorporate the patient voice into your
strategy to provide a better standard of care
for your customers
• Identify how patient access programmes and risk sharing models will
improve patient access to essential medicines in South Africa
• Learn what patient groups need and how they engage with
government and medical schemes to increase reimbursement for
your products
• Discover new approaches to help pharma work with patients to
improve education and access to drugs
Lauren Pretorius
CEO
Campaigning for Cancer
PANEL: We’re all in this together – ensure
your marketing, market access medical
teams best work together
• Adopt strategies that improve cross-team communication to avoid
information being lost
• Understand how a market access approach will enhance your marketing
strategy and how to integrate your key account strategy into this
• Hear expert insight on the optimum business unit structure across
top pharma companies in South Africa
Vaychel Raman
Head of Market Access
Novartis
Tom Molokoane
Head of Market Access
Novo Nordisk
Gerdi Strydom
Head of Health Value,
Southern Africa
Pfizer
CASE STUDY: Understand the effects
of transformational leadership on your
salesperson’s intention to quit and the impact
of this on your organization’s bottom line
• Examine South African sales rep feedback on their job satisfaction
• Understand trends in sales rep commitment to their organisation
• Evaluate sales rep perception of the ethical climate of their employer
and the impact this has on their attitude towards their work
Karina Rogers
Marketing Manager
Aurobindo Pharma
PANEL: Deliver 21st century marketing
in a medical context
• Explore which of the marketing methodologies provide reliably strong ROI
• Determine how social media can be integrated into your marketing
strategy to best engage with the market
• Understand the differences between generics, ethical and CAMS
approaches and what can be learnt from each
• Examine successful marketing campaigns by pharma companies
globally and what can be learnt from them to enhance your
marketing strategy
Avinash Dhaniraj
Head of Commercial
Mylan
Karina Rogers
Marketing Manager
Aurobindo Pharma
Martin van den Berg
Head of Marketing
Boehringer Ingelheim
Wesley Hughes
Customer Excellence
Manager
Abbvie
Conference Agenda
www.eyeforpharma.com/southafrica

7. www.eyeforpharma.com/southafrica
The pharmaceutical industry in South
Africa suffers from poor image, which
is making it difficult to readily enter into
fruitful cooperation with the government.
In South Africa, pharma is an easy target for criticism.
Shying away from telling its own story directly to the
public, the industry has failed to establish itself as a
trusted partner in healthcare. Seen as profit-driven,
pharma doesn’t inspire the confidence necessary to
build a sustainable relationship with the government
or patients. But that assessment isn’t fair. “We do a lot
to improve healthcare. That’s why we exist. We live to
find new medicines; we are driven by the passion of
people who wake up in the morning to deliver new
molecules that address a myriad of diseases, including
cancer, HIV/AIDS, or other devastating communicable
and non-communicable illnesses. Making money is a
by-product,” said Konji Sebati, CEO, The Innovative
Pharmaceutical Association South Africa (IPASA).
Changing this perception is high on Dr Sebati’s agenda.
“We haven’t told our story because we’ve always had
our backs against the wall. In that situation it is natural
to throw your hands in the air and do nothing.”
Keeping patents is part of the problem
The industry has received particularly strong disapproval
over their insistence on maintaining patents. In South
Africa, there is a 20-year period of product protection,
during which generic companies cannot produce a given
molecule. After the patent lapses, it’s everybody’s game.
Many activists oppose this piece of legislation. Some
argue against patents altogether, others say the period
of protection should be shortened, yet others fight to
make it impossible to extend intellectual property rights
to products described as“incremental innovation.”
While it’s easy to oppose patents, those arguing against
them need to realize two things. For example, the
clock starts ticking at the moment of discovery, which
happens before clinical trials can begin, and with
registration delays, it is easily ten years before a drug
reaches patients. “By then you are usually left with 10-12
years of protection,” Dr Sebati said.
Another, far more important realization, is that
incremental innovation needs to be protected because
without it, there is no chance for real breakthroughs.
The development of insulin is a good example. Dr
Sebati described: “It started with large needles, frequent
injections, constant blood sugar measurements, etc.
Now you have once-daily administration, jet injectors,
insulin pumps, patches – none of that would be
available without incremental innovation.”
Too much regulation doesn’t leave room to maneuver
But image problems aren’t the only issues keeping up
pharma execs late at night. “[Pharma] in South Africa
is highly regulated, to a point where the amount of
legislation you have to abide by makes it very challenging
to innovate. Regulation is good, but it should be balanced
in a way that leaves room for growth, technology,
knowledge transfer, and cooperation,” Dr Sebati explained.
For example, Dr Sebati proposed, there should be an
opportunity to introduce different pricing policies for
the public and private sectors. With 84% of South African
population covered by the public insurance, it should be
made possible to introduce tiered pricing for the public
sector. “We could charge market prices for the private
sector, and lower the prices for the public sector with the
government guarantee of volume purchased,” Dr Sebati
pointed out. “Ideally, we would be able to negotiate
with the government, so that cutting-edge medicines
eyeforpharma
caught up with Konji,
CEO of IPASA...
By
Zuzanna
Fiminska
Continued...
INSIGHT

8. Opportunities for
solution providers
Business opportunities include:
• 1-to-1 meetings with key
decision makers
• Demonstrate thought leadership
to a room of senior level executives
• Show off your latest products and
services in our exhibition hall
• Build your brand with exclusive
promotional opportunities
• Host interactive workshops with
core clients and prospects...
and much more!
eyeforpharma on demand grants
you access to exclusive reports
– plus audio, video, reports and
whitepapers from ALL of our market
access and commercial conferences
and research projects.
Access eyeforpharma on demand
for a 4 week taster with a Gold Pass.
See more:
• The foresight to anticipate
what’s next
• The inspiration to explore
what’s possible
• The edge to go above
and beyond
Maximise your return on investment
at this industry-leading event by
increasing your profile with our
exciting range of sponsorship
opportunities, contact:
Joseph Hargreaves
Business Development Manager
eyeforpharma
+44 207 375 7583
jhargreaves@eyeforpharma.com
www.eyeforpharma.com/southafrica
reach publicly-funded patients, too. This way we could support government
on access to all medicines, irrespective of it being a generic or an originator
medicine to the public sector as well, but currently the law doesn’t allow that.”
As a resolve to the status quo, Dr Sebati suggests that there should be an
open line of communication between pharma and the government, which
could include regular meetings of the partners to discuss issues and to
strategize together on the best ways to deliver healthcare to all. “We should
have a forum, where we meet every three months or so to discuss healthcare
issues,” Dr Sebati offered. This way would enable the government and pharma
to deal with each other in an open and evidence-based manner. In addition,
it would facilitate problem solving as issues arise. “We have recently been
inundated with questions about stock-outs at healthcare facilities, when
members know that their medicines have definitely left the warehouses; a
clear indication of lacking inventory control skills, efficient logistics, and
distribution plans. Pharma is well-positioned to help. We have the expertise.
We know logistics. We can partner with the government and train people. I
would very much wish to see that cooperation with time. I don’t want us to
only talk to each other when there is a crisis.”
Nevertheless, the government is not the only stakeholder that needs to be
brought on board. Conscious of that, Dr Sebati is now looking for the best
way to cooperate with e.g. patient groups. Although still unclear about the
best manner in which to proceed, she’s looking at ways that can lead to a
sustainable model of cooperation. “That’s one of the things we can do to build
bridges with our most important stakeholder, the patient,” Dr Sebati stated.
Accusations over medicine costs
Pharma also have to face accusations from some funders asserting that the
biggest cost drivers in healthcare are medicines. Such attitude ignores the
many factors around the discovery and the positive wave of new life-saving,
life-prolonging, personalized medicines that will be approved in the coming
years. As a result of those approvals, those drugs will shorten the disease
suffering, get patients well and back to work earlier, with less side effects, and
a huge economic benefit to the government in the end. “What we should all
be doing as health partners and in this
health value chain, is spend less time
pointing fingers and fighting battles
through the media, and more time
sitting together and with government
addressing the funding requirement
for these medicines. Pricing is already
regulated. This debate should no
longer be happening.”
In spite of all these problems,
incremental steps toward improving
the situation are being made, and with
some good will from all participating
stakeholders, interests can be aligned
and South Africa’s healthcare system
can go a long way.
...from previous
“Spend less time
pointing fingers
and fighting battles
through the media,
and more time
sitting together and
with government
addressing the funding
requirement for these
medicines”

9. Registration: choose your pass type
Delegate Details
Mr/Mrs/Ms/Dr: First name: Last name:
Company: Position/Title:
Telephone: Fax: Email:
Address: Postcode: Country:
Payment
I enclose a cheque/draft for:
(Payable to FC Business Intelligence Ltd)
Please invoice my company:
Purchase Order Number:
Please charge my credit card: Amex Visa Mastercard
Credit card number:
Expiry date:
Security number:
Name on card:
Signature:
www.eyeforpharma.com/southafrica/register.php
1 ONLINE
Send this form by fax to +44 20 7375 7172
4 FAX
The eyeforpharma Registration Team at
register@eyeforpharma.com
3 E-MAIL
eyeforpharma on +44 20 7375 7222
2 CALL
4 Easy Ways
To Register
Today!
Last Chance – Expires 19 February $1850 R30,400* $750 R12,300* $650 R10,700*
Full Price $2000 R32,900* $800 R13,000* $700 R11,500*
For Solution Providers Consultants
Last Chance – Expires 19 February $1550 R25,500* $650 R10,700* $550 R9,055*
Full Price $1700 R27,900* $700 R11,500* $600 R9,870*
For Pharma Biotech Collaboration Pass Gold Silver
GROUP RATE MOST POPULAR
TERMS CONDITIONS Places are transferable without any charge. Cancellations before 8th February 2016 incur an administrative charge of 25%. if you cancel your registration after 8th February 2016 we will be obliged to charge the
full fee. Please note – you must notify eyeforpharma in writing of a cancellation, or we will be obliged to charge the full fee. The organizers reserve the right to make changes to the programme without notice. All prices displayed are
exclusive of VAT unless otherwise stated but, VAT will be charged, where applicable, at the prevailing rate on the invoice date and the relevant details will appear on the invoice. NB: FULL PAYMENT MUST BE RECEIVED BEFORE THE EVENT.
3Ms Collaboration Pass
Bring your marketing, market access and medical teams
along. Get 3 gold passes which include:
• Access to all conference sessions, exhibition networking area
• Access to speaker pdf slides and audio
• 4 week subscription to eyeforpharma On Demand, includes
access to all event materials since 2013 and our premium
reports. More details here: eyeforpharma.com/on-demand
See prices below. Email Giselle on
GQuartin@eyeforpharma.com
Gold Pass
• Access to all conference sessions,
exhibition networking area
• Access to speaker pdf slides
and audio
• 4 week subscription to
eyeforpharma On Demand, includes
access to all event materials since
2013 and our premium reports.
More details here:
eyeforpharma.com/on-demand
Silver Pass
• Access to all
conference sessions,
exhibition
networking area
www.eyeforpharma.com/southafrica
* Conversion rate as of the 13 January 2016

10. Overcome barriers to entry: embrace
an access-based marketing strategy
Sandton, Johannesburg | March 8–9 | The only forum connecting pharma, government and payers
COMMERCIAL EXCELLENCE AND MARKET ACCESS
SOUTH AFRICA 2016
www.eyeforpharma.com/southafrica
Collaborate
Establish relationships with all
your key stakeholders, industry
leaders and innovators
Network
Spend over 6 hours networking
with 100+ pharma, experts, payers
and key decision makers
Learn
25+ thought leaders help you maximize
your learning in just 2 days with industry-led
agenda case studies and panel discussions
#efpCEMA
Dr Konji Sebati
CEO
IPASA
Jaime César de Moura
Oliveira
Immediate Past Director
ANVISA (Brazilian FDA)
Inez Naidu
Head of Medicines
Unit
Discovery Health
Gerrit Doevendans
Head of Market
Access South Africa
Boehringer
Ingelheim
Gerdi Strydom
Head of Health Value,
Southern Africa
Pfizer
Belinda Bhoodoo
Director, Corporate
Affairs Market
Access
Eli Lilly Co
FOSTER COLLABORATIVE THINKING
and consensus amongst various stakeholders
REMOVE BARRIERS TO PRESCRIBING
Encourage cross-functional working across your 3Ms:
• Marketing • Market Access • Medical teams
DESIGN WITH YOUR PAYERS
Don’t just design your strategy for payers, design it with them –
and build long-term partnerships
MAP YOUR MARKET WITH INTELLIGENCE
AND PRECISION
And better prepare for future submissions
Gold Sponsor Strategic Partners Media Partners
Limited
Passes
Available